Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification

PLoS Pathogens

Volumn 6, Issue 2, 2010, Pages

  Balsitis, Scott J ^a   Williams, Katherine L ^a   Lachica, Ruben ^a   Flores, Diana ^a   Kyle, Jennifer L ^a   Mehlhop, Erin ^b   Johnson, Syd ^c   Diamond, Michael S ^b   Beatty, P Robert ^d   Harris, Eva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Analytical Sciences   (United States)

^d University of California Berkeley   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CROSS REACTING ANTIBODY; FC RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E60 N297Q; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DENGUE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; GENETIC ENGINEERING; MOUSE; NONHUMAN; VIREMIA; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; CELL SEPARATION; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; PASSIVE IMMUNIZATION; SERODIAGNOSIS; SURFACE PLASMON RESONANCE;

DENGUE VIRUS; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CELL SEPARATION; CROSS REACTIONS; DENGUE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOHISTOCHEMISTRY; MICE; NEUTRALIZATION TESTS; SURFACE PLASMON RESONANCE; VIRAL LOAD;

EID: 77649262630     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000790     Document Type: Article

References (55)

1. Rothman AL (2004) Dengue: defining protective versus pathologic immunity. J Clin Invest 113: 946-951.
2. Halstead SB (2007) Dengue. Lancet 370: 1644-1652.
3. WHO (1997) Dengue haemorrhagic fever: diagnosis, treatment, prevention, and control. Geneva: World Health Organization.
4. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421-467.
5. Kliks SC, Nimmanitya S, Nisalak A, Burke DS (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411-419.
6. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, et al. (2008) Dengue in Vietnamese infants-results of infection-enhancement assays correlate with agerelated disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198: 516-524.
7. Halstead SB (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140: 527-533.
8. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422-9427.
9. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E (2006) A murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208-10217.
10. Kyle JL, Beatty PR, Harris E (2007) Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis 195: 1808-1817.
11. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG (2007) A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 195: 665-674.
12. Balsitis S, Coloma J, Castro G, Alava A, Flores D, et al. (2009) Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg 80: 416-424.
13. Kyle JL, Balsitis S, Zhang L, Beatty PR, Harris E (2008) Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380: 296-303.
14. Kraus AA, Messer W, Haymore LB, de Silva AM (2007) Comparison of plaqueand flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45: 3777-3780.
15. Funahara Y, Sumarmo, Shirahata A, Setiabudy-Dharma R (1987) DHF characterized by acute type DIC with increased vascular permeability. Southeast Asian J Trop Med Public Health 18: 346-350.
16. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, et al. (2004) Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 189: 221-232.
17. Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, et al. (2004) IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol 73: 230-234.
18. Jessie K, Fong MY, Devi S, Lam SK, Wong KT (2004) Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 189: 1411-1418.
19. Hume DA, Robinson AP, MacPherson GG, Gordon S (1983) The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoietic organs. J Exp Med 158: 1522-1536.
20. Hume DA, Perry VH, Gordon S (1984) The mononuclear phagocyte system of the mouse defined by immunohistochemical localisation of antigen F4/80: macrophages associated with epithelia. Anat Rec 210: 503-512.
21. Pierson TC, Diamond MS (2008) Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10: e12.
22. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, et al. (2004) Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189: 990-1000.
23. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, et al. (2008) Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 82: 3939-3951.
24. Crill WD, Chang GJ (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78: 13975-13986.
25. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, et al. (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80: 12149-12159.
26. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11: 522-530.
27. Tao MH, Morrison SL (1989) Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143: 2595-2601.
28. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, et al. (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 67: 8882-8890.
29. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G (2003) Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 35: 33-42.
30. Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA (2007) Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol 81: 5518-5526.
31. Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, et al. (1998) Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 72: 9729-9737.
32. An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K (1999) Development of a novel mouse model for dengue virus infection. Virology 263: 70-77.
33. Blaney JE Jr, Johnson DH, Manipon GG, Firestone CY, Hanson CT, et al. (2002) Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300: 125-139.
34. Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, et al. (2003) Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21: 3919-3929.
35. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R (2005) Dengue fever in humanized NOD/SCID mice. J Virol 79: 13797-13799.
36. Kuruvilla JG, Troyer RM, Devi S, Akkina R (2007) Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice. Virology 369: 143-152.
37. Hotta H, Murakami I, Miyasaki K, Takeda Y, Shirane H, et al. (1981) Inoculation of dengue virus into nude mice. J Gen Virol 52: 71-76.
38. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, et al. (2004) Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78: 2701-2710.
39. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, et al. (2008) A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4: e29. doi:10.1371/journal.-ppat.0040029.
40. Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD (2009) A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 5: e1000614. doi:10.1371/journal.ppat.1000614.
41. Weiss RC, Scott FW (1981) Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 4: 175-189.
42. Barrett AD, Gould EA (1986) Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol 67 (Pt 11): 2539-2542.
43. Gould EA, Buckley A (1989) Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol 70 (Pt 6): 1605-1608.
44. Broom AK, Wallace MJ, Mackenzie JS, Smith DW, Hall RA (2000) Immunisation with gamma globulin to murray valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against australian encephalitis: evaluation in a mouse model. J Med Virol 61: 259-265.
45. Wallace MJ, Smith DW, Broom AK, Mackenzie JS, Hall RA, et al. (2003) Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 84: 1723-1728.
46. Takano T, Kawakami C, Yamada S, Satoh R, Hohdatsu T (2008) Antibodydependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection. J Vet Med Sci 70: 1315-1321.
47. Rothman AL (2003) Immunology and immunopathogenesis of dengue disease. Adv Virus Res 60: 397-419.
48. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2-9.
49. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, et al. (2002) High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 186: 1165-1168.
50. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos de Chacon I, et al. (1999) Dengue virus structural differences that correlate with pathogenesis. J Virol 73: 4738-4747.
51. Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, et al. (2007) Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196: 416-424.
52. Shresta S, Kyle JL, Robert Beatty P, Harris E (2004) Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 319: 262-273.
53. Holden KL, Stein D, Pierson TC, Ahmed A, Clyde K, et al. (2006) Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer to the top of the 3′ stem-loop structure. Virology 344: 439-452.
54. van den Broek MF, Muller U, Huang S, Zinkernagel RM, Aguet M (1995) Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev 148: 5-18.
55. Houng HH, Hritz D, Kanesa-thasan N (2000) Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3′-noncoding sequence. J Virol Methods 86: 1-11.